Migrastatics: Redirecting R&D in Solid Cancer Towards Metastasis?

Tannock, 2016, Limits to precision cancer medicine, N. Engl. J. Med., 375, 1289, 10.1056/NEJMsb1607705 Fernandes, 2017, Cancer, checkpoint inhibitors, and confusion, Lancet Oncol., 18, e632, 10.1016/S1470-2045(17)30810-0 Editorial, 2017, Calling time on the immunotherapy gold rush, Lancet Oncol., 18, 981, 10.1016/S1470-2045(17)30521-1 Fernandes, 2019, Solid cancer: the new tumour spread endpoint opens novel opportunities, Br. J. Cancer, 121, 513, 10.1038/s41416-019-0536-0 Brábek, 2016, Pragmatic medicine in solid cancer: a translational alternative to precision medicine, Onco. Targets Ther., 9, 1839, 10.2147/OTT.S103832 Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N. Engl. J. Med., 378, 1408, 10.1056/NEJMoa1715546 Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N. Engl. J. Med., 378, 2465, 10.1056/NEJMoa1800536 Fizazi, 2019, Darolutamide in nonmetastatic, castration-resistant prostate cancer, N. Engl. J. Med., 380, 1235, 10.1056/NEJMoa1815671 Gandalovičová, 2017, Migrastatics – anti-metastatic and anti-invasion drugs: promises and challenges, Trends Cancer, 3, 391, 10.1016/j.trecan.2017.04.008 Chambers, 2002, Dissemination and growth of cancer cells in metastatic sites, Nat. Rev. Cancer., 2, 563, 10.1038/nrc865 Brábek, 2012, Affordable cancer care, Lancet Oncol., 1, 32 Tang, 2018, Trial watch: the clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors, Nat. Rev. Drug Discov., 17, 854, 10.1038/nrd.2018.210 Bates, 2019, PD-1 Pandemonium at the American Association for Cancer Research (AACR) annual meeting, Oncologist, 24, 571, 10.1634/theoncologist.2019-0281 Kuhn, 2012